Antiverse Seed
Cardiff, GB · 6 known investors
Antiverse is a techbio company that uses machine learning and cell line engineering to design de novo antibody therapeutics against difficult targets such as G-protein coupled receptors and ion channels. It works with pharmaceutical companies and develops its own internal antibody pipeline across multiple indications.
Also known as Antiverse
Founders & leadership
Investors · 6
Company profile
researched Aug 2026Antiverse is an antibody discovery company that combines generative AI models with laboratory work to design de novo biologics against targets considered difficult to drug, particularly G-protein coupled receptors (GPCRs) and other transmembrane proteins. Its models are trained on data purpose-built for GPCRs and transmembrane proteins, which the company says has been accumulated since 2017, and it maintains a library of more than 240 proprietary stable cell lines for GPCRs and ion channels used to raise true binder discovery rates.
The platform supports sequence- or structure-based generative design across biologic formats that contain a heavy chain, including monoclonal antibodies and VHH/VH-VL constructs. An integrated dry-lab and wet-lab workflow creates an iterative design-test feedback loop for lead generation, with prioritized clones characterized in about one month because they retain their natural conformation. The company reports a 2000x higher hit rate versus a naive library in the discovery of functional agonist antibodies for a Class A GPCR. Alongside partnered discovery work with pharmaceutical companies and other organizations, Antiverse presents its own pipeline.
Business model
Antiverse offers AI-driven antibody discovery through partnerships with pharmaceutical companies and other organizations, while also advancing an internal pipeline; its website separately lists platform, pipeline and partnership sections.
Latest developments
The company announced that its Series A closed at $9.3M and that it entered a research agreement with the Cystic Fibrosis Foundation.
▸Full profile — market position, technology, go-to-market, geography
Market position
Positions itself as an AI-powered discovery company focused on functional, developable biologics for targets that broad protein models and naive libraries address poorly, citing about a decade of work in the area.
Specialized GPCR and transmembrane-protein training data built since 2017, a proprietary collection of more than 240 stable cell lines, and reported 2000x higher hit rates versus naive libraries for functional agonist antibodies against a Class A GPCR.
Technology
Generative AI models for de novo antibody design, trained on data specialized for GPCRs and transmembrane proteins rather than broad protein corpora, coupled with over 240 proprietary stable cell lines for GPCRs and ion channels. Design can proceed from sequence or structure and covers any biologic format with a heavy chain (mAbs, VHH/VH-VL). Integrated computational and wet-lab operations enable iterative generative cycles, with prioritized clones characterized in roughly one month.
Go-to-market
Pharmaceutical companies and research organizations seeking biologics against challenging targets such as GPCRs and ion channels.
Geography
Headquartered in Cardiff, United Kingdom.
Compiled by commissioned research from 3 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsCompany website announcement stating that the Series A round closed at $9.3M.
$9.3M source ↗
Antiverse announced a research agreement with the Cystic Fibrosis Foundation.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 3
primary sources listed
- Antiverse Seedantiverse.io · web
3 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Antiverse Seed do?
- Antiverse applies generative AI and engineered cell lines to de novo antibody discovery against GPCRs and other hard targets.
- Who founded Antiverse Seed?
- Antiverse Seed was founded by Ben H..
- Who are Antiverse Seed's investors?
- Antiverse Seed's investors include Cambridge Angels group, Deep Science Ventures, DOMiNO Ventures, Future Planet Capital, Innospark Ventures, UK Innovation & Science Seed Fund.
- Where is Antiverse Seed headquartered?
- Antiverse Seed is headquartered in Cardiff, GB.